JP6791556B2 - 均一な、高モル質量環状イミノエーテルポリマーの調製のための方法 - Google Patents
均一な、高モル質量環状イミノエーテルポリマーの調製のための方法 Download PDFInfo
- Publication number
- JP6791556B2 JP6791556B2 JP2017501382A JP2017501382A JP6791556B2 JP 6791556 B2 JP6791556 B2 JP 6791556B2 JP 2017501382 A JP2017501382 A JP 2017501382A JP 2017501382 A JP2017501382 A JP 2017501382A JP 6791556 B2 JP6791556 B2 JP 6791556B2
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- oxazoline
- solvent
- reaction mixture
- imino ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000642 polymer Polymers 0.000 title claims description 147
- 238000000034 method Methods 0.000 title claims description 70
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 title claims description 67
- 125000004122 cyclic group Chemical group 0.000 title claims description 66
- 238000002360 preparation method Methods 0.000 title description 6
- 239000011541 reaction mixture Substances 0.000 claims description 80
- 239000000178 monomer Substances 0.000 claims description 78
- 239000002904 solvent Substances 0.000 claims description 60
- 238000006116 polymerization reaction Methods 0.000 claims description 51
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 27
- 239000003999 initiator Substances 0.000 claims description 24
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 claims description 23
- -1 2-substituted-2-oxazoline Chemical class 0.000 claims description 11
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims description 10
- GXCJLVVUIVSLOQ-UHFFFAOYSA-N 2-propyl-4,5-dihydro-1,3-oxazole Chemical compound CCCC1=NCCO1 GXCJLVVUIVSLOQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 9
- 150000001768 cations Chemical group 0.000 claims description 8
- GUXJXWKCUUWCLX-UHFFFAOYSA-N 2-methyl-2-oxazoline Chemical compound CC1=NCCO1 GUXJXWKCUUWCLX-UHFFFAOYSA-N 0.000 claims description 7
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000002918 oxazolines Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims 1
- 238000012656 cationic ring opening polymerization Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000001542 size-exclusion chromatography Methods 0.000 description 30
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000012535 impurity Substances 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 12
- 239000004926 polymethyl methacrylate Substances 0.000 description 12
- SJHPCNCNNSSLPL-UHFFFAOYSA-N 4-(ethoxymethylene)-2-phenyloxazol-5-one Chemical compound O1C(=O)C(=COCC)N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 229920001519 homopolymer Polymers 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 229920006187 aquazol Polymers 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000001376 precipitating effect Effects 0.000 description 5
- FVEZUCIZWRDMSJ-UHFFFAOYSA-N 2-propan-2-yl-4,5-dihydro-1,3-oxazole Chemical compound CC(C)C1=NCCO1 FVEZUCIZWRDMSJ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000012861 aquazol Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- VJFBCIZMCZRCQH-UHFFFAOYSA-N 3-(2-methoxy-4,5-dihydro-1,3-oxazol-4-yl)propanoic acid Chemical compound COC=1OCC(N=1)CCC(=O)O VJFBCIZMCZRCQH-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- YEDDVXZFXSHDIB-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluoropropan-1-ol Chemical compound OC(F)(F)C(F)(F)C(F)F YEDDVXZFXSHDIB-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- ZXTHWIZHGLNEPG-UHFFFAOYSA-N 2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC=C1 ZXTHWIZHGLNEPG-UHFFFAOYSA-N 0.000 description 2
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 150000004893 oxazines Chemical class 0.000 description 2
- CUNPJFGIODEJLQ-UHFFFAOYSA-M potassium;2,2,2-trifluoroacetate Chemical compound [K+].[O-]C(=O)C(F)(F)F CUNPJFGIODEJLQ-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- HMOZDINWBHMBSQ-UHFFFAOYSA-N 2-[3-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC(C=2OCCN=2)=C1 HMOZDINWBHMBSQ-UHFFFAOYSA-N 0.000 description 1
- VYYANIUXTTXFJR-UHFFFAOYSA-N 2-but-3-enyl-4,5-dihydro-1,3-oxazole Chemical compound C=CCCC1=NCCO1 VYYANIUXTTXFJR-UHFFFAOYSA-N 0.000 description 1
- VERUITIRUQLVOC-UHFFFAOYSA-N 2-butyl-4,5-dihydro-1,3-oxazole Chemical compound CCCCC1=NCCO1 VERUITIRUQLVOC-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 150000000376 2-oxazolines Chemical class 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CPELPSYDDMKTKL-UHFFFAOYSA-N 3-(4,5-dihydro-1,3-oxazol-2-yl)-2-methoxypropanoic acid Chemical compound COC(CC=1OCCN=1)C(=O)O CPELPSYDDMKTKL-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- MVPPADPHJFYWMZ-IDEBNGHGSA-N chlorobenzene Chemical group Cl[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 MVPPADPHJFYWMZ-IDEBNGHGSA-N 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- NIRYAMUQLIEZLP-UHFFFAOYSA-N methyl 3-(4,5-dihydro-1,3-oxazol-2-yl)propanoate Chemical compound COC(=O)CCC1=NCCO1 NIRYAMUQLIEZLP-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- ROQYGSVHXLIXGO-UHFFFAOYSA-N prop-2-ynyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OCC#C ROQYGSVHXLIXGO-UHFFFAOYSA-N 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
a)環状イミノエーテルモノマー及び任意選択で溶媒を含む、第1の液体反応混合物を用意するステップ、
b)カチオン開環重合によって第1の反応混合物中で環状イミノエーテルモノマーを重合して、(i)重合物及び(ii)溶媒及び/又は未反応の環状イミノエーテルモノマーを含有する、重合した第1の反応混合物を生成するステップ、
c)重合した第1の反応混合物に含有されている重合物から、溶媒及び/又は未反応の環状イミノエーテルモノマーを分離するステップ、
d)分離された未反応の環状イミノエーテルモノマー及び/又は分離された溶媒を、その他の成分(溶媒、モノマー及び/又は開始剤)と組み合わせることによって、環状イミノエーテルモノマー及び溶媒を含有する、第2の液体反応混合物を用意するステップ、並びに
e)カチオン開環重合によって第2の反応混合物中で環状イミノエーテルモノマーを重合して、少なくとも100の重合度(DP)を有する、均一なポリマーを生成ステップ
を含む。
θmax=1.2+(DP−250)/8000(250≦DP<900の場合)
θmax=1.28125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.48125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
a)環状イミノエーテルモノマー及び任意選択で溶媒を含む、第1の液体反応混合物を用意するステップ、
b)カチオン開環重合によって第1の反応混合物中で環状イミノエーテルモノマーを重合して、(i)重合物及び(ii)溶媒及び/又は未反応の環状イミノエーテルモノマーを含有する、重合した第1の反応混合物を生成するステップ、
c)重合した第1の反応混合物に含有されている重合物から、溶媒及び/又は未反応の環状イミノエーテルモノマーを分離するステップ、
d)分離された未反応の環状イミノエーテルモノマー及び/又は分離された溶媒を、その他の成分と組み合わせることによって、環状イミノエーテルモノマー及び溶媒を含有する、第2の液体反応混合物を用意するステップ、並びに
e)カチオン開環重合によって第2の反応混合物中で環状イミノエーテルモノマーを重合して、少なくとも100の重合度(DP)を有する、均一なポリマーを生成するステップ
を含む。
θmax=1.2+(DP−250)/8000(250≦DP<900の場合)
θmax=1.28125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.48125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
θmax=1.15+(DP−250)/8000(250≦DP<900の場合)
θmax=1.23125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.43125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
θmax=1.1+(DP−250)/8000(250≦DP<900の場合)
θmax=1.18125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.38125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
θmax=1.2+(DP−250)/8000(250≦DP<900の場合)
θmax=1.28125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.48125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
θmax=1.15+(DP−250)/8000(250≦DP<900の場合)
θmax=1.23125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.43125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
θmax=1.1+(DP−250)/8000(250≦DP<900の場合)
θmax=1.18125+(DP−900)/500(900≦DP<1000の場合)
θmax=1.38125+(DP−1000)/9770(1000≦DPの場合)
によって計算される。
2−エチル−2−オキサゾリン(EtOx)を分留して、128℃沸騰中心カットを収集した。次に、数日間ナトリウム上で撹拌し、脱気し、きれいな貯蔵器中へ蒸留した。2−メチル−2−オキサゾリン(MeOx)を同じ方法で精製した。
一方の側にシュレンクフラスコ、その反対側に三方活栓付き丸底フラスコを取り付けた、きれいで乾燥した蒸留橋を、コーンソケットによって真空ラインに取り付けた。ガラス又はテフロンコーティングされた撹拌子を、それぞれの側に付けた。系を空にし、アルゴンで再び満たした。アルゴンの逆流に向かって、トリメチルシリルクロリド(TMSCl)2〜5mLを、シュレンクフラスコ上の活栓によって加え、系を孤立させた。TMSClを、液体窒素中にフラスコを浸漬することによって凍結させ、系を空にした。解凍に際して、TMSClは、主要な大気成分となり、ガラス上でヒドロキシル基と反応して、系を疎水性にした。少なくとも30分後、系をアルゴンでパージし、TMSClを除去し、フラスコを水、アセトン及び石油エーテルで濯いだ後で、気流で乾燥させた。
いくつかの異なるカラムシステム使用して、分散度を測定した。分解能が高ければ高いほど、ポリマーは、より狭い。全ての場合において、ポリマーは、PMMA標準試料と同じ狭さであった。
1. 2×PL HFIPGel及びガード − 低分解能、中範囲(特に断りのない限り、デフォルト)
2. 2×PSS PFG100Å及びガード − 高分解能、限定された範囲(spec.100〜100,000Da)
3. 2×PSS PFG Linear XL及びガード − 中分解能及び高範囲(spec.100〜3,000,000Da)
末端のアミン基を有するポリ(2−エチル−2−オキサゾリン)公称重量40kDaを、定量的転化近くまで重合することによって調製した。
末端のアミン基を有する、非常に高い分子量(約100kDa)のポリ(2−エチル−2−オキサゾリン)を、以下の通り調製した。
実施例1の手順に従って、一連の異なる分子質量を有するPEtOxを調製し、結果を表1に要約した。これらは、オンライン粘度測定法によって分析され、補正率0.777を、HFIPについて測定した。HFIPの溶出ピークはまさにポアソン分布であり、PMMA標準試料の幅に類似していた。
末端のアミン基を有する、ブロックコポリ(2−エチル−2−オキサゾリン)(2−イソプロピル−2−オキサゾリン)を、以下の通り調製した。
末端のアミン基を有する、2−エチル−2−オキサゾリンと2−メトキシカルボキシエチル−2−オキサゾリン(MestOx)との統計コポリマーを、以下の通り調製した。
末端のアミン基を有する、100kDaのポリ(2−エチル−2−オキサゾリン)を、以下の通り60℃で調製した。
トリブロックポリ(2−n−プロピル−2−オキサゾリン)(2−エチル−2−オキサゾリン)(2−n−プロピル−2−オキサゾリン)コポリマーを、以下の通り調製した。
末端のアミンを有する、218kDaのポリ(2−エチル−2−オキサゾリン)を、以下の通り60℃で調製した。
10kDaのポリ(2−n−プロピル−2−オキサゾリン)を、以下の通り調製した。
アミン末端基を有する、50kDaのポリ(2−メチル−2−オキサゾリン)を、以下の通り調製した。
Claims (16)
- 5個又は6個の環員を有する環状イミノエーテルモノマーのカチオン開環重合によって、高モル質量の均一なポリマーを製造する方法であって、
a)環状イミノエーテルモノマー、開始剤並びに任意選択で、任意選択で置換された芳香族炭化水素、スルホラン、ジメチルアセトアミド及びそれらの混合物から選択される溶媒を含む、第1の液体混合物を用意するステップ、
b)カチオン開環重合によって前記第1の液体混合物中で環状イミノエーテルモノマーを重合して、(i)重合物及び(ii)溶媒及び/又は未反応の環状イミノエーテルモノマーを含有する、重合した第1の反応混合物を生成するステップ、
c)前記重合した第1の反応混合物に含有されている重合物から、溶媒及び/又は未反応の環状イミノエーテルモノマーを分離するステップ、
d)前記分離された未反応の環状イミノエーテルモノマー及び/又は前記分離された溶媒を、その他の成分と組み合わせることによって、環状イミノエーテルモノマー、開始剤並びに任意選択で置換された芳香族炭化水素、スルホラン、ジメチルアセトアミド及びそれらの混合物から選択される溶媒を含有する、第2の液体混合物を用意するステップ、並びに
e)カチオン開環重合によって前記第2の液体混合物中で前記環状イミノエーテルモノマーを重合して、少なくとも100かつ10000を超えない重合度(DP)を有する、均一なポリマーを生成するステップ
を含む方法。 - 前記環状イミノエーテルモノマーが、任意選択で置換されたオキサゾリンである、請求項1に記載の方法。
- 前記環状イミノエーテルモノマーが、任意選択で2−置換された、2−オキサゾリンである、請求項2に記載の方法。
- 溶媒及び/又は未反応の環状イミノエーテルモノマーが、蒸留を用いて、前記重合した第1の反応混合物に含有されている重合物から分離される、請求項1〜3のいずれか一項に記載の方法。
- 溶媒及び/又は未反応の環状イミノエーテルモノマーが、深冷蒸留を用いて、前記重合した第1の反応混合物に含有されている重合物から分離される、請求項4に記載の方法。
- 溶媒が、前記重合した第1の反応混合物に含有されている重合物から分離され、前記分離された溶媒が、環状イミノエーテルモノマーと組み合わされて、前記第2の液体混合物を生成する、請求項1〜5のいずれか一項に記載の方法。
- 未反応の環状イミノエーテルモノマーが、前記重合した第1の反応混合物に含有されている重合物から分離され、前記分離された未反応の環状イミノエーテルモノマーが、溶媒と組み合わされて、前記第2の液体混合物を生成する、請求項1〜5のいずれか一項に記載の方法。
- 溶媒及び未反応の環状イミノエーテルモノマーが、前記重合した第1の反応混合物に含有されている重合物から分離され、その他の成分と組み合わされて、前記第2の液体混合物を生成する、請求項1〜5のいずれか一項に記載の方法。
- 重合物から分離された前記溶媒及び/又は未反応の環状イミノエーテルモノマーが、10ppm未満の重合物を含有する、請求項6〜8のいずれか一項に記載の方法。
- 前記均一なポリマーが、200超の重合度(DP)を有する、請求項1〜9のいずれか一項に記載の方法。
- 前記均一なポリマーが、250超の重合度(DP)を有する、請求項1〜10のいずれか一項に記載の方法。
- 前記均一なポリマーが、400超の重合度(DP)を有する、請求項1〜11のいずれか一項に記載の方法。
- 2−メチル−2−オキサゾリン、2−エチル−2−オキサゾリン、2−n−プロピル−2−オキサゾリン、2−i−プロピル−2−オキサゾリン及びそれらの組合せから選択される、2−置換−2−オキサゾリンモノマーに由来する繰返し単位を少なくとも50重量%含むポリオキサゾリンポリマーであって、少なくとも900かつ10000を超えない重合度(DP)及び1.15未満の分散度を有する、ポリオキサゾリンポリマー。
- 前記2−置換−2−オキサゾリンが、2−エチル−オキサゾリンである、請求項13に記載のポリオキサゾリンポリマー。
- 1.08未満の分散度を有する、請求項13又は14に記載のポリオキサゾリンポリマー。
- 請求項13〜15のいずれか一項に記載のポリオキサゾリンポリマーを含有する、医薬組成物又は医療デバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14177587.4 | 2014-07-18 | ||
EP14177587 | 2014-07-18 | ||
PCT/EP2015/065829 WO2016008817A1 (en) | 2014-07-18 | 2015-07-10 | Method for the preparation of uniform, high molar mass cyclic imino ether polymers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017529412A JP2017529412A (ja) | 2017-10-05 |
JP6791556B2 true JP6791556B2 (ja) | 2020-11-25 |
Family
ID=51220407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017501382A Active JP6791556B2 (ja) | 2014-07-18 | 2015-07-10 | 均一な、高モル質量環状イミノエーテルポリマーの調製のための方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10118991B2 (ja) |
EP (1) | EP3204442B1 (ja) |
JP (1) | JP6791556B2 (ja) |
CN (1) | CN107075115B (ja) |
AU (1) | AU2015289329B2 (ja) |
BR (1) | BR112017000911B1 (ja) |
CA (1) | CA2955301C (ja) |
ES (1) | ES2701172T3 (ja) |
WO (1) | WO2016008817A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017182610A1 (en) * | 2016-04-22 | 2017-10-26 | Universiteit Gent | Methods for the preparation of cyclic imino ether polymers |
JP7227151B2 (ja) | 2017-03-22 | 2023-02-21 | ジェネンテック, インコーポレイテッド | 眼障害の治療のために最適化された抗体組成物 |
EP3764994A1 (en) | 2018-03-16 | 2021-01-20 | Universiteit Gent | Drug formulations comprising polyoxazolines as matrix excipient |
WO2020099553A1 (en) | 2018-11-14 | 2020-05-22 | Universiteit Gent | Poly(2-oxazoline)s and methods for preparing them |
EP3741832B1 (en) * | 2019-05-24 | 2022-06-01 | Infineum International Limited | Nitrogen-containing lubricating oil additives |
EP4222248A1 (en) | 2020-09-30 | 2023-08-09 | Universiteit Maastricht | 3d structures for cell growth |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445621A1 (de) | 1964-03-18 | 1969-03-13 | Huels Chemische Werke Ag | Verfahren zur Reinigung von delta?-Oxazolinen |
US4281137A (en) | 1980-02-20 | 1981-07-28 | The Dow Chemical Company | Purification of 2-oxazolines |
EP1930361B1 (en) * | 2005-09-01 | 2014-04-16 | Japan Science and Technology Agency | Random copolymer of oxazoline |
EP2134181A4 (en) * | 2007-02-28 | 2011-09-28 | Serina Therapeutics Inc | ACTIVATED POLYOXAZOLINS AND COMPOSITIONS CONTAINING THEREOF |
US20100197888A1 (en) | 2007-07-31 | 2010-08-05 | Polyplus Transfection | Method for Manufacturing Linear Polyethylenimine (PEI) for Transfection Purpose and Linear PEI Obtained with Such Method |
JP5560436B2 (ja) * | 2010-02-05 | 2014-07-30 | Jfeケミカル株式会社 | MnZnNi系フェライト |
WO2011162366A1 (ja) | 2010-06-25 | 2011-12-29 | 東レ株式会社 | 水溶性ポリマー及び水溶性ナノ粒子複合体 |
US9180202B2 (en) * | 2012-01-02 | 2015-11-10 | Universiteit Gent | Polyoxazoline polymers and methods for their preparation, conjugates of these polymers and medical uses thereof |
US20160130396A1 (en) * | 2013-03-15 | 2016-05-12 | Basf Se | Polyoxazoline Chelating Agent |
-
2015
- 2015-07-10 US US15/326,866 patent/US10118991B2/en active Active
- 2015-07-10 AU AU2015289329A patent/AU2015289329B2/en active Active
- 2015-07-10 CA CA2955301A patent/CA2955301C/en active Active
- 2015-07-10 JP JP2017501382A patent/JP6791556B2/ja active Active
- 2015-07-10 BR BR112017000911-0A patent/BR112017000911B1/pt active IP Right Grant
- 2015-07-10 ES ES15736496T patent/ES2701172T3/es active Active
- 2015-07-10 CN CN201580039070.0A patent/CN107075115B/zh active Active
- 2015-07-10 WO PCT/EP2015/065829 patent/WO2016008817A1/en active Application Filing
- 2015-07-10 EP EP15736496.9A patent/EP3204442B1/en active Active
-
2018
- 2018-08-02 US US16/053,700 patent/US10781287B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10781287B2 (en) | 2020-09-22 |
CA2955301C (en) | 2023-01-17 |
CN107075115A (zh) | 2017-08-18 |
CA2955301A1 (en) | 2016-01-21 |
BR112017000911B1 (pt) | 2023-04-11 |
CN107075115B (zh) | 2020-05-29 |
US10118991B2 (en) | 2018-11-06 |
EP3204442A1 (en) | 2017-08-16 |
ES2701172T3 (es) | 2019-02-21 |
JP2017529412A (ja) | 2017-10-05 |
US20180346649A1 (en) | 2018-12-06 |
WO2016008817A1 (en) | 2016-01-21 |
AU2015289329B2 (en) | 2018-12-06 |
AU2015289329A1 (en) | 2017-01-19 |
US20170210853A1 (en) | 2017-07-27 |
EP3204442B1 (en) | 2018-09-12 |
BR112017000911A2 (pt) | 2017-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6791556B2 (ja) | 均一な、高モル質量環状イミノエーテルポリマーの調製のための方法 | |
Rothemund et al. | Preparation of polyphosphazenes: a tutorial review | |
KR101767852B1 (ko) | 자유 라디칼 중합성 에틸렌계 불포화 폴록사머 및 폴록사민의 합성 | |
US10717825B2 (en) | Cationic mucic acid polymer-based delivery system | |
KR20180068852A (ko) | 미셀 안정성이 향상된 양친성 블록 공중합체 조성물 및 이를 포함하는 약학 조성물 | |
CN106866978B (zh) | 自催毁嵌段聚合物及其制备方法 | |
EP1757631A1 (en) | Amphiphilic triblock copolymers comprising poly(2-vinyl pyridine) block and poly(alkyl isocyanate) block, and the preparation method thereof | |
Kong et al. | Synthesis of water soluble polyrotaxanes by end-capping polypseudo-rotaxanes of γ-CDs with PHEMA-PPO-PEO-PPO-PHEMA using ATRP of MPC | |
Sato et al. | Precise synthesis of α, ω-chain-end functionalized poly (dimethylsiloxane) with azide groups based on metal-free ring-opening polymerization and a quantitative azidation reaction | |
Dadkhah et al. | Synthesis of hyperbranched polyglycerols using ascorbic acid as an activator | |
Czaplewska et al. | Functionalized PEG‐b‐PAGE‐b‐PLGA triblock terpolymers as materials for nanoparticle preparation | |
JPWO2018016513A1 (ja) | 末端にアミノ基を有するポリマーの製造方法 | |
Choi et al. | Novel Macromolecular Self-organization of Poly (ethylene glycol)-block-poly (L-histidine): pH-induced Formation of Core-shell Nanoparticles in Aqueous Media | |
Sogah et al. | Simultaneous block copolymerization via macromolecular engineering. One-step, one-pot initiation of living free radical and cationic polymerization | |
KR20160140707A (ko) | 알킬렌 옥사이드 중합체의 제조 방법 | |
WO2018207806A1 (ja) | 重合体および重合体の製造方法 | |
JP3873923B2 (ja) | ポリオキシアルキレン誘導体の製造方法 | |
KR101001734B1 (ko) | 고순도의 메톡시폴리에틸렌글리콜에틸말레이마이드의분석방법 | |
JPH04332728A (ja) | ポリスチレン誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180706 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190828 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200424 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201030 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6791556 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |